Recent data of lack of response of K-ras-mutated colorectal tumours to cetuximab (Karapetis et al, 2008) may help rationalise the use of this selection criteria in future studies with bortezomib and cetuximab. The gene discussed is KRAS; the disease is colorectal neoplasm.